Profile data is unavailable for this security.
About the company
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
- Revenue in USD (TTM)0.00
- Net income in USD-38.68m
- Incorporated2021
- Employees163.00
- LocationProKidney Corp2000 Frontis Plaza Blvd., Suite 250WINSTON-SALEM 27103United StatesUSA
- Phone+1 (336) 999-7028
- Websitehttps://prokidney.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aura Biosciences Inc | 0.00 | -80.69m | 539.71m | 88.00 | -- | 2.82 | -- | -- | -1.79 | -1.79 | 0.00 | 3.86 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Altimmune Inc | 409.00k | -101.35m | 545.82m | 59.00 | -- | 3.58 | -- | 1,334.54 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Q32 Bio Inc | 0.00 | -65.02m | 546.19m | 41.00 | -- | 16.21 | -- | -- | -16.24 | -16.24 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -31.38 | -34.98 | -36.35 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.2725 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Regenxbio Inc | 84.33m | -238.81m | 552.92m | 344.00 | -- | 1.83 | -- | 6.56 | -5.03 | -5.03 | 1.76 | 6.09 | 0.1463 | -- | 3.27 | 245,136.60 | -41.43 | -16.75 | -51.75 | -19.08 | 54.36 | 78.27 | -283.19 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 560.02m | 150.00 | -- | 2.84 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| Alector Inc | 61.51m | -158.41m | 563.11m | 241.00 | -- | 4.73 | -- | 9.16 | -1.71 | -1.71 | 0.6607 | 1.21 | 0.1035 | -- | -- | 252,082.00 | -26.66 | -20.00 | -35.58 | -23.81 | -- | -- | -257.54 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Monte Rosa Therapeutics Inc | 14.98m | -119.39m | 568.31m | 103.00 | -- | 2.77 | -- | 37.95 | -1.83 | -1.83 | 0.2215 | 3.35 | 0.0528 | -- | 33.69 | 112,594.00 | -42.10 | -- | -47.48 | -- | -- | -- | -797.26 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Larimar Therapeutics Inc | 0.00 | -64.77m | 569.16m | 42.00 | -- | 2.87 | -- | -- | -1.15 | -1.15 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -40.11 | -42.22 | -43.16 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| ProKidney Corp | 0.00 | -38.68m | 579.35m | 163.00 | -- | -- | -- | -- | -0.5905 | -0.5905 | 0.00 | -7.73 | 0.00 | -- | -- | 0.00 | -27.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | 67.17 | -- | -- | -- |
| Celcuity Inc | 0.00 | -82.59m | 586.93m | 55.00 | -- | 3.32 | -- | -- | -2.74 | -2.74 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -37.03 | -37.32 | -39.38 | -39.16 | -- | -- | -- | -- | -- | -- | 0.3525 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| ACELYRIN Inc | 0.00 | -299.80m | 588.87m | 130.00 | -- | 1.03 | -- | -- | -3.06 | -3.06 | 0.00 | 5.71 | 0.00 | -- | -- | 0.00 | -40.33 | -- | -43.71 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -22.62m | 591.11m | 28.00 | -- | 11.54 | -- | -- | -0.4458 | -0.4458 | 0.00 | 0.8189 | 0.00 | -- | -- | 0.00 | -36.89 | -38.31 | -44.60 | -43.34 | -- | -- | -- | -- | -- | -22.18 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| SS Innovations International Inc | 14.41m | -23.68m | 597.59m | 239.00 | -- | 35.19 | -- | 41.47 | -0.1396 | -0.1396 | 0.0847 | 0.0995 | 0.6003 | 2.28 | 5.08 | 60,293.01 | -98.66 | -161.38 | -216.15 | -449.76 | 28.42 | -79.79 | -164.35 | -495.77 | 0.9128 | -45.39 | 0.4172 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
| Sangamo Therapeutics Inc | 12.28m | -249.68m | 597.59m | 405.00 | -- | 25.22 | -- | 48.68 | -1.38 | -1.38 | 0.0664 | 0.1138 | 0.0587 | -- | 7.45 | 30,313.58 | -119.44 | -26.09 | -153.51 | -31.04 | -- | -- | -2,033.68 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -95.90m | 616.12m | 66.00 | -- | 2.35 | -- | -- | -1.31 | -1.31 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -36.84 | -41.34 | -38.72 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| Third Harmonic Bio Inc | 0.00 | -32.74m | 616.46m | 42.00 | -- | 2.38 | -- | -- | -0.8204 | -0.8204 | 0.00 | 6.31 | 0.00 | -- | -- | 0.00 | -11.87 | -- | -12.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
Data as of Nov 08 2024. Currency figures normalised to ProKidney Corp's reporting currency: US Dollar USD
36.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley Investment Management, Inc.as of 30 Sep 2024 | 13.91m | 11.03% |
| Suvretta Capital Management LLCas of 28 Aug 2024 | 12.34m | 9.79% |
| GBM Administradora de Activos, SA de CV SOSIas of 30 Aug 2024 | 5.88m | 4.67% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 3.87m | 3.07% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.33m | 2.64% |
| Bleichroeder LPas of 30 Jun 2024 | 2.61m | 2.07% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.23m | 0.98% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.09m | 0.87% |
| Brown University Investment Officeas of 30 Sep 2024 | 1.00m | 0.79% |
| Santander Private Banking Gestion SA SGIICas of 30 Jun 2024 | 602.59k | 0.48% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
